Expert: Autologous anti-BCMA CAR T-cell therapy using Arcellx D-Domain binder technology. High CAR expression without tonic signaling, rapid BCMA target release.
Everyday: Genetically modified immune cells that target BCMA protein on myeloma cells.
Targets: ["BCMA"]